Antonia S J, Wagner H, Williams C, Alberts M, Hubbell D, Robinson L, Hilstro J, Ruckdeschel J C
Thoracic Oncology Program, H. Lee Moffitt Cancer Center, Tampa, FL 33612-9497, USA.
Semin Oncol. 1995 Aug;22(4 Suppl 9):34-7.
Nine patients with stage IIIB non-small cell lung cancer were entered into a phase II trial designed to determine the feasibility of giving a combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin concurrent with thoracic radiation. Paclitaxel was given as a 24-hour infusion (135 mg/m2) followed by cisplatin (75 mg/m2) every 4 weeks, for a total of four cycles. Thoracic radiation was given concurrently with the first two cycles of chemotherapy, for a total dose of 64.8 Gy over 6 weeks. Neutropenia and esophagitis were the most common toxicities, with 66% of patients experiencing grade 3 or 4 neutropenia and 55% experiencing grade 3 or 4 esophagitis. Grade 3 pulmonary toxicity developed in 33% of patients. All patients were able to receive the full dose of radiation, although half of the patients required some modification of the chemotherapy regimen. There was one complete response and four partial responses, yielding a 56% overall response rate. This study demonstrates that it is feasible to treat patients with stage IIIB non-small cell lung cancer with paclitaxel/cisplatin plus concurrent thoracic radiation, with a degree of toxicity comparable with that associated with a degree of toxicity comparable with that associated with other concurrent combined-modality regimens for this disease.
9例IIIB期非小细胞肺癌患者进入一项II期试验，该试验旨在确定给予紫杉醇（泰素；百时美施贵宝公司，新泽西州普林斯顿）加顺铂与胸部放疗同时进行的可行性。紫杉醇采用24小时输注（135mg/m²），随后每4周给予顺铂（75mg/m²），共4个周期。胸部放疗与前两个化疗周期同时进行，6周内总剂量为64.8Gy。中性粒细胞减少和食管炎是最常见的毒性反应，66%的患者出现3级或4级中性粒细胞减少，55%的患者出现3级或4级食管炎。33%的患者发生3级肺部毒性。所有患者均能够接受全量放疗，尽管一半的患者需要对化疗方案进行一些调整。有1例完全缓解和4例部分缓解，总缓解率为56%。本研究表明，用紫杉醇/顺铂加同期胸部放疗治疗IIIB期非小细胞肺癌患者是可行的，其毒性程度与该疾病其他同期联合治疗方案的毒性程度相当。
